Exparel liposomal (bupivacaine)
- Region
- 🇪🇺 EU
- Active substance
- bupivacaine
- Company
- Pacira Ireland Limited
- Status
- Authorised
- Therapeutic area
- Acute Pain
- CHMP opinion
- Thu 17 Sep 2020
- EU approval
- Mon 16 Nov 2020
- Application
- EMEA/H/C/004586
- ATC
- N01BB01
- Official record
- www.ema.europa.eu
Indication
Exparel liposomal is indicated: in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zynrelef Withdrawn · Heron Therapeutics, B.V.
Follow Exparel liposomal
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.